Wednesday, biopharmaceutical company Cell Therapeutics, Inc. (CTIC) said that its antitumour agent Pixantrone achieved secondary endpoint of progression-free survival in the end-phase EXTEND trial conducted on advanced, relapsed aggressive non-Hodgkin's lymphoma or NHL patients.
Earlier, Cell Therapeutics announced that the drug-candidate's randomized trial achieved primary endpoint of significant higher rate of confirmed and unconfirmed complete remissions, compared to patients treated with standard chemotherapy. Additionally, the company said Pixantrone treatment considerably increased the overall response rate.
The results were based on the end-phase single-agent trial of pixantrone conducted on 140 patients with relapsed, aggressive non-Hodgkin's lymphoma who had received two or more prior therapies and were sensitive to anthracyclines treatment.
The study followed the special protocol assessment approval from the US Food and Drug Administration in 2004, wherein pixantrone had received fast track designation for NHL.
Commenting on the results, James Bianco, Chief Executive Officer said that Pixantrone, the first agent to show progression-free survival on NHL patients supports a priority review designation on our New Drug Application, or NDA.
On Tuesday, the company announced that it expects to submit a rolling NDA and request for priority review on its antitumour agent for relapsed aggressive NHL in the first quarter of 2009.
The stock closed Tuesday, at $0.1145 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.